Cyclo Therapeutics Announces Data from Ongoing Niemann-Pick Disease Type C1 (NPC1) Trial
Cyclo Therapeutics, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Author: Tamas Sohajda
Cyclolab R&D Director
FDA Expands EUA for SBECD-enabled Remdesivir
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With
FDA Approves New KYPROLIS® (SBECD-enabled carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone
Approval Based on the CANDOR and EQUULEUS Studies in Patients With Relapsed/Refractory Multiple Myeloma Amgen today announced the U.S. Food and
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that it
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
Gilead Sciences, Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration
Pfizer agrees to manufacture Gilead’s coronavirus drug remdesivir
Pfizer has agreed to manufacture and supply Gilead Sciences’ antiviral drug remdesivir, the pharmaceutical giant announced Friday. The multiyear agreement will support efforts to
Breakthrough Therapy Designation Granted for SBECD-enabled Pevonedistat
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its SBECD
European Commission secures EU access to Remdesivir for treatment of COVID-19
The European Commission has signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand
Wacker on cyclodextrins in the COVID fight
The world’s largest cyclodextrin producer, Wacker Chemie has recently published a press release on cyclodextrins and their role in the
Cyclodextrin dimers to treat atherosclerotic plaques by targeting various forms of cholesterol
SENS Research Foundation (USA, California) filed a PCT patent application (WO2020142716) that was recently published. In the invention, a new class